-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Based on the above factors, COMPASS Pathways plc gets an overall score of 1/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US20451W1018 |
Sector | Healthcare |
Industry | Medical Care Facilities |
Market Cap | 370M |
---|---|
Beta | 2.35 |
PE Ratio | None |
Target Price | 17.3 |
Dividend Yield | None |
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CMPS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025